These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 34516026)

  • 1. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
    J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
    Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
    Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
    Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
    J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.
    Liao Y; Zhang Y; Zhao H; Pu J; Zhao Z; Li D; Fan S; Yu L; Xu X; Wang L; Jiang G; Liu L; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):1112-1115. PubMed ID: 34057040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
    N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
    Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
    N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
    [No Abstract]   [Full Text] [Related]  

  • 14. Audio Interview: How Well Are Covid-19 Vaccines Working?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
    [No Abstract]   [Full Text] [Related]  

  • 15. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
    N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
    [No Abstract]   [Full Text] [Related]  

  • 16. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
    N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    Wang GL; Wang ZY; Duan LJ; Meng QC; Jiang MD; Cao J; Yao L; Zhu KL; Cao WC; Ma MJ
    N Engl J Med; 2021 Jun; 384(24):2354-2356. PubMed ID: 33822491
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter to the Editor about "Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers before the booster dose of the vaccine".
    Daungsupawong H; Wiwanitkit V
    Rev Clin Esp (Barc); 2024; 224(7):481. PubMed ID: 38944200
    [No Abstract]   [Full Text] [Related]  

  • 20. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
    Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
    N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 45.